[go: up one dir, main page]

NO20053076D0 - Farmasoytisk formulering med en uloselig aktiv forbindelse. - Google Patents

Farmasoytisk formulering med en uloselig aktiv forbindelse.

Info

Publication number
NO20053076D0
NO20053076D0 NO20053076A NO20053076A NO20053076D0 NO 20053076 D0 NO20053076 D0 NO 20053076D0 NO 20053076 A NO20053076 A NO 20053076A NO 20053076 A NO20053076 A NO 20053076A NO 20053076 D0 NO20053076 D0 NO 20053076D0
Authority
NO
Norway
Prior art keywords
active compound
pharmaceutical formulation
insoluble active
insoluble
formulation
Prior art date
Application number
NO20053076A
Other languages
English (en)
Other versions
NO20053076L (no
Inventor
Jeffrey G Weers
Thomas E Tarara
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32713146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053076(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of NO20053076D0 publication Critical patent/NO20053076D0/no
Publication of NO20053076L publication Critical patent/NO20053076L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20053076A 2002-12-31 2005-06-23 Farmasoytisk formulering med en uloselig aktiv forbindelse. NO20053076L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43721002P 2002-12-31 2002-12-31
PCT/US2003/041703 WO2004060351A2 (en) 2002-12-31 2003-12-31 Pharmaceutical formulation with an insoluble active agent for pulmonary administration

Publications (2)

Publication Number Publication Date
NO20053076D0 true NO20053076D0 (no) 2005-06-23
NO20053076L NO20053076L (no) 2005-09-13

Family

ID=32713146

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053076A NO20053076L (no) 2002-12-31 2005-06-23 Farmasoytisk formulering med en uloselig aktiv forbindelse.

Country Status (18)

Country Link
US (1) US20040156792A1 (no)
EP (1) EP1589947B2 (no)
JP (1) JP2006513236A (no)
KR (1) KR20050095838A (no)
CN (1) CN1741789A (no)
AU (1) AU2003300137A1 (no)
BR (1) BR0317810A (no)
CA (1) CA2511523C (no)
EA (1) EA200501001A1 (no)
ES (1) ES2589578T5 (no)
HU (1) HUP0500846A3 (no)
MX (1) MXPA05007158A (no)
NO (1) NO20053076L (no)
PL (1) PL378270A1 (no)
PT (1) PT1589947T (no)
TR (1) TR200502522T2 (no)
WO (1) WO2004060351A2 (no)
ZA (1) ZA200505155B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
ES2364636T3 (es) * 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
AU2003302274A1 (en) * 2002-12-31 2004-07-29 Novartis Ag Aerosolizable pharmaceutical formulation for fungal infection therapy
KR101511196B1 (ko) 2003-05-28 2015-04-10 노바르티스 아게 아미노산 및/또는 인지질로 부분 또는 완전 코팅된 수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의 분무 건조법
US8513204B2 (en) * 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
WO2006026502A1 (en) * 2004-08-27 2006-03-09 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
US20090032427A1 (en) * 2005-09-29 2009-02-05 Nektar Therapeutics Receptacles and Kits, Such as for Dry Powder Packaging
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
WO2007092088A1 (en) * 2005-12-28 2007-08-16 Nektar Therapeutics Compositions comprising amphotericin b
EP1986679B1 (en) * 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
DE102006053375A1 (de) * 2006-11-10 2008-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mischung von Pulvern
JP4879349B2 (ja) * 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
PL220269B1 (pl) 2008-04-21 2015-09-30 Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego
CA2724009C (en) 2008-05-15 2016-10-11 Novartis Ag Pulmonary delivery of a fluoroquinolone
ES2750359T3 (es) 2009-03-18 2020-03-25 Incarda Therapeutics Inc Dosis unitarias, aerosoles, kits y procedimientos para tratar afecciones cardíacas mediante administración pulmonar
PT3130396T (pt) 2009-03-27 2021-05-12 Bend Res Inc Processo de secagem por pulverização
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
TR200904500A2 (tr) 2009-06-10 2009-10-21 Öner Levent Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
EP2611530B1 (en) 2010-09-03 2019-01-16 Bend Research, Inc. Spray-drying apparatus and methods of using the same
EP2618924A1 (en) 2010-09-24 2013-07-31 Bend Research, Inc. High-temperature spray drying process and apparatus
CN103228266B (zh) 2010-10-29 2017-11-14 健康科学西部大学 三元混合物制剂
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
EP3102216A4 (en) * 2014-02-03 2017-08-09 The Board of Trustees of The Leland Stanford Junior University Formulations for microparticle delivery of zinc protoporphyrins
EP3212169B1 (en) 2014-10-31 2021-01-13 Bend Research, Inc. Process for forming active domains dispersed in a matrix
CN104587457B (zh) * 2015-01-13 2017-03-22 广东海大畜牧兽医研究院有限公司 一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法
WO2017109678A1 (en) * 2015-12-24 2017-06-29 Philip Morris Products S.A. Nicotine particle capsule
CA3012333A1 (en) 2016-02-01 2017-08-10 Incarda Therapeutics, Inc. Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
WO2018209107A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
MX2019014671A (es) * 2017-06-28 2020-02-07 Philip Morris Products Sa Contenedor con particulas para su uso con un inhalador.
ES3040411T3 (en) 2018-03-22 2025-10-30 Incarda Therapeutics Inc A novel method to slow ventricular rate
GB201817865D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
GB201817860D0 (en) 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolised formulation
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
CN119365218A (zh) 2022-03-21 2025-01-24 伊利诺伊大学评议会 包含脂质包覆的两性霉素b晶体的离子通道假体组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US437210A (en) 1890-09-30 Electric street-car
SE408265B (sv) * 1975-12-12 1979-06-05 Draco Ab Anordning for koldioxiddriven endosaerosol, avsedd for inhalering
US4247066A (en) * 1978-02-21 1981-01-27 General Dynamics Corporation Airfoil variable cambering device and method
IT1116047B (it) * 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
DE3634952A1 (de) * 1986-10-14 1988-04-21 Bayer Ag Imidazo-pyrrolo-pyridin-derivate
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
EP0940154B1 (en) * 1991-07-02 2007-04-18 Nektar Therapeutics Device for delivering aerosolized medicaments
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
JP3388896B2 (ja) * 1994-08-08 2003-03-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
ATE287703T1 (de) * 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5976574A (en) * 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
KR100575070B1 (ko) * 1997-09-29 2006-05-03 넥타르 테라퓨틱스 안정화된 생활성 제제 및 이의 사용 방법
US6257233B1 (en) * 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
AU4602399A (en) † 1998-06-30 2000-01-24 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Prolonged release ophthalmic compositions containing a fluoroquinolone
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
PT1280520E (pt) † 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US6357490B1 (en) * 2000-08-22 2002-03-19 Advanced Inhalation Research, Inc. System, method and apparatus for filling containers
EP1343372A2 (en) * 2000-12-21 2003-09-17 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents

Also Published As

Publication number Publication date
MXPA05007158A (es) 2005-09-21
BR0317810A (pt) 2005-11-29
WO2004060351A2 (en) 2004-07-22
EP1589947A2 (en) 2005-11-02
EP1589947B2 (en) 2019-01-30
JP2006513236A (ja) 2006-04-20
US20040156792A1 (en) 2004-08-12
ES2589578T3 (es) 2016-11-15
CA2511523A1 (en) 2004-07-22
WO2004060351A3 (en) 2004-09-30
HUP0500846A2 (en) 2008-05-28
ZA200505155B (en) 2006-04-26
HUP0500846A3 (en) 2008-10-28
PL378270A1 (pl) 2006-03-20
PT1589947T (pt) 2016-09-05
EP1589947B1 (en) 2016-06-15
CN1741789A (zh) 2006-03-01
EA200501001A1 (ru) 2005-12-29
TR200502522T2 (tr) 2005-09-21
KR20050095838A (ko) 2005-10-04
AU2003300137A1 (en) 2004-07-29
ES2589578T5 (es) 2019-07-23
EP1589947B8 (en) 2016-08-24
NO20053076L (no) 2005-09-13
CA2511523C (en) 2013-10-15

Similar Documents

Publication Publication Date Title
NO20053076D0 (no) Farmasoytisk formulering med en uloselig aktiv forbindelse.
DK1545467T3 (da) Faste farmaceutiske formuleringer omfattende telmisartan
NO20043998L (no) Oral administreringsform for tungtloselige basiske aktive virkestoffer
ATE374016T1 (de) Tablette mit hohem wirkstoffgehalt
DK2060189T3 (da) Aktivstofholdige adsorbater
ITTO20010005A0 (it) Formulazione farmaceutica.
DE50212546D1 (de) Orale darreichungsformen für propiverin oder seinen pharmazeutisch annehmbaren salzen mit verlängerter wirkstofffreisetzung
DE60323235D1 (de) Pramipexol-tablette mit verzögerter wirkstoffabgabe
PT1501534E (pt) Formulacoes farmaceuticas
NO20053150D0 (no) System for administrasjon av medisin.
NO20033384L (no) Farmasoytisk formulering
KR20050009999A (ko) 약제학적 제제
DE60308372D1 (de) Dosierungsverabreichungsvorrichtung
NO20033785L (no) Farmasöytisk formulering
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
NO20035627D0 (no) Farmasöytisk formulering
DK1596870T3 (da) Höjdosis-iblandronatformulering
NL1023790A1 (nl) Farmaceutische samenstellingen met antibiotische activiteit.
IT1311921B1 (it) Composti farmaceutici.
NL1028193A1 (nl) Farmaceutisch werkzame verbindingen.
DK1624869T3 (da) Doseringsform indeholdende pantoprazol som aktiv bestanddel
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
DE60324703D1 (de) Barbitursäure derivaten.
EP1581196A4 (en) SÄURELABILE MEDICINAL COMPOSITIONS
ITMI20020921A0 (it) Dispositivo per la sommistrazione di farmaci

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application